Context Therapeutics Inc.

As of June 30, 2026, Context Therapeutics, Inc. carries a market capitalization of 45.39M, placing it among publicly traded companies globally. Its enterprise value stands at 7.97M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Context Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Context Therapeutics, Inc. has 91.88M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Context Therapeutics, Inc. maintains a current ratio of 5.81, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Context Therapeutics, Inc. posted a negative return on equity (ROE) of -76.14, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -68.96, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 14.25, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Context Therapeutics, Inc.'s stock has declined approximately 80.00% over the past 52 weeks. The 50-day moving average sits at 0.31, while the 200-day moving average is 1.26.

Over the twelve months ended June 30, 2026, Context Therapeutics, Inc. generated - - in revenue and converted that into -40.23M in net income, yielding earnings per share of -0.43. EBITDA reached -42.63M, while operating income came in at -42.65M.

As of June 30, 2026, Context Therapeutics, Inc. holds 37.63M in cash and equivalents against 214,441.50 in total debt, resulting in a net debt position of -37.63M. Total book value stands at 33.41M, with working capital of 33.20M providing operational flexibility.

Context Therapeutics, Inc. produced -29.73M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.80M in capital expenditures, free cash flow totaled -31.53M - equivalent to -0.33 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -67.65: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Context Therapeutics, Inc. shareholders.

As of June 30, 2026, Context Therapeutics, Inc. has an Altman Z-Score of -3.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.